Summary
This study demonstrated that plant-derived indigo supplementation attenuates intestinal inflammation in ulcerative colitis through a gut microbiota-dependent pathway. The mechanism involves enrichment of Roseburia intestinalis and increased production of the bacterial metabolite butyrate, which promotes anti-inflammatory Treg differentiation whilst suppressing pro-inflammatory Th17 cells via mTORC1/HIF-1α-mediated metabolic reprogramming. Clinical samples from UC patients confirmed dysbiosis and aberrant CD4+ T cell differentiation, supporting the potential of microbiota-targeted supplementation as a novel immunotherapy for inflammatory bowel disease.
Regional applicability
The study geography is not specified in the metadata, limiting direct applicability assessment to United Kingdom clinical practice. However, the mechanistic insights into the gut-immune axis and microbiota-derived metabolites are likely relevant to UC management in any healthcare system; translation would require confirmation in United Kingdom patient populations and consideration of regulatory pathways for botanical supplements.
Key measures
Mucosal inflammation markers, CD4+ T cell differentiation (Th17/Treg ratios), gut microbiota composition, butyrate concentration, mTORC1/HIF-1α signalling, glucose metabolism reprogramming
Outcomes reported
The study measured the effect of indigo supplementation on intestinal inflammation, CD4+ T cell differentiation, gut microbiota composition, and butyrate production in both mouse models and ulcerative colitis patients. Results showed indigo decreased mucosal inflammation through microbiota-dependent mechanisms involving Roseburia intestinalis enrichment and butyrate-mediated Th17/Treg immune regulation.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.